Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
311 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Huntington's Disease - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2015', provides an overview of the Huntington's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Huntington's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Huntington's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Huntington's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Huntington's Disease Overview 10 Therapeutics Development 11 Pipeline Products for Huntington's Disease - Overview 11 Pipeline Products for Huntington's Disease - Comparative Analysis 12 Huntington's Disease - Therapeutics under Development by Companies 13 Huntington's Disease - Therapeutics under Investigation by Universities/Institutes 18 Huntington's Disease - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Huntington's Disease - Products under Development by Companies 23 Huntington's Disease - Products under Investigation by Universities/Institutes 28 Huntington's Disease - Companies Involved in Therapeutics Development 30 Addex Therapeutics Ltd 30 AFFiRiS AG 31 Alnylam Pharmaceuticals, Inc. 32 Angita B.V. 33 Astellas Pharma Inc. 34 Azevan Pharmaceuticals, Inc. 35 BioCrea GmbH 36 BioMarin Pharmaceutical Inc. 37 BrainStorm Cell Therapeutics Inc. 38 Chong Kun Dang Pharmaceutical Corp. 39 Chronos Therapeutics Limited 40 EncephRx, Inc. 41 Evotec AG 42 Galenea Corp. 43 Genervon Biopharmaceuticals, LLC 44 Genethon 45 Ipsen S.A. 46 Isis Pharmaceuticals, Inc. 47 Kadmon Corporation, LLC 48 KineMed, Inc. 49 Living Cell Technologies Limited 50 Medesis Pharma S.A. 51 Neuralstem, Inc. 52 Neurimmune Holding AG 53 NeuroNascent, Inc. 54 New World Laboratories, Inc. 55 nLife Therapeutics, S.L. 56 NsGene A/S 57 Omeros Corporation 58 Oryzon Genomics S.A. 59 Pfizer Inc. 60 PharmatrophiX, Inc. 61 Prana Biotechnology Limited 62 Provid Pharmaceuticals, Inc. 63 QR Pharma, Inc. 64 Raptor Pharmaceuticals Inc 65 reMYND NV 66 RestorGenex Corporation 67 Rhenovia Pharma Limited 68 Sangamo BioSciences, Inc. 69 SOM Innovation Biotech SL 70 Teva Pharmaceutical Industries Limited 71 TyrNovo Ltd. 72 Ultragenyx Pharmaceutical Inc. 73 uniQure N.V. 74 Vaccinex, Inc. 75 Vertex Pharmaceuticals Incorporated 76 VistaGen Therapeutics , Inc. 77 VivaCell Biotechnology Espana S.L. 78 Voyager Therapeutics, Inc. 79 Vybion, Inc. 80 Zenobia Therapeutics, Inc. 81 Huntington's Disease - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Target 83 Assessment by Mechanism of Action 86 Assessment by Route of Administration 89 Assessment by Molecule Type 91 Drug Profiles 93 AK-7 - Drug Profile 93 ALN-HTT - Drug Profile 95 Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile 97 Antisense Oligonucleotide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 98 Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 99 ASP-2905 - Drug Profile 100 AV-101 - Drug Profile 101 BN-82451 - Drug Profile 103 Carbenoxolone sodium - Drug Profile 104 Cell Therapy for Huntington's Disease - Drug Profile 105 CNB-001 - Drug Profile 106 CP-2 - Drug Profile 108 cysteamine DR - Drug Profile 109 DC-012 - Drug Profile 112 dipraglurant IR - Drug Profile 113 dutetrabenazine ER - Drug Profile 114 ED-11 - Drug Profile 116 ENC-1001 - Drug Profile 117 fisetin - Drug Profile 118 Gene Therapy to Activate CNTF for Huntington's Disease - Drug Profile 119 Gene Therapy to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 120 GM-609 - Drug Profile 121 HSB-13 - Drug Profile 122 INT-41 - Drug Profile 123 ISIS-HTTRx - Drug Profile 125 JM-6 - Drug Profile 126 JR-100 - Drug Profile 127 JRP-655 - Drug Profile 128 JRP-900 - Drug Profile 129 KL-00148 - Drug Profile 130 laquinimod sodium - Drug Profile 131 lithium citrate - Drug Profile 135 LM11A-31BHS - Drug Profile 137 Memantine Nitrone - Drug Profile 139 MP-101 - Drug Profile 140 NI-302 - Drug Profile 141 NNI-362 - Drug Profile 142 NNI-370 - Drug Profile 144 noscapine - Drug Profile 145 NP-42T - Drug Profile 146 NsG-33 - Drug Profile 147 NSI-566 - Drug Profile 148 NT-219 - Drug Profile 150 NTCELL - Drug Profile 151 NWL-154 - Drug Profile 153 OGCx-833 - Drug Profile 154 OMS-527 - Drug Profile 155 ORY-2001 - Drug Profile 156 OXD-5 - Drug Profile 157 PBF-999 - Drug Profile 158 PBT-2 - Drug Profile 159 Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 161 Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 163 PF-02545920 - Drug Profile 164 Posiphen - Drug Profile 166 pridopidine hydrochloride - Drug Profile 168 PRO-289 - Drug Profile 170 RDC-5 - Drug Profile 171 Recombinant Protein for Alzheimer's Disease and Huntington's Disease - Drug Profile 173 RES-529 - Drug Profile 174 Rhedar - Drug Profile 176 RNAi Gene Therapy to Inhibit Huntingtin for Huntington's Disease - Drug Profile 177 RO-5461861 - Drug Profile 178 Rycal - Drug Profile 179 Small Molecule for Huntington's Disease - Drug Profile 180 Small Molecule for Huntington's Disease - Drug Profile 181 Small Molecule for Huntington's Disease - Drug Profile 182 Small Molecule for Huntington's Disease - Drug Profile 183 Small Molecule for Parkinson's Disease and Huntington's Disease - Drug Profile 184 Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 185 Small Molecule to Antagonize NMDA receptor for Huntington's Disease - Drug Profile 186 Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease - Drug Profile 187 Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease - Drug Profile 188 Small molecules for Huntington Disease - Drug Profile 189 Small Molecules for Huntington's Disease - Drug Profile 191 Small Molecules to Activate HSF-1 for Huntington's Disease - Drug Profile 192 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 193 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 195 Small Molecules to Antagonize NMDA Receptor for Neurodegenerative Disorders - Drug Profile 196 Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 197 Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 198 Small Molecules to Inhibit Caspase-6 for Huntingtons Disease - Drug Profile 199 Small Molecules to Inhibit DREAM Protein for Huntington's Disease - Drug Profile 200 Small Molecules to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 201 Small Molecules to Inhibit LSD-1 And MAO-B for Huntington Disease - Drug Profile 202 Small Molecules to Inhibit PDE-10A for Huntington's Disease - Drug Profile 203 Small Molecules to Target Free Radical for Huntington's Disease - Drug Profile 204 SNB-2401 - Drug Profile 205 SNB-4050 - Drug Profile 206 SOM-3355 - Drug Profile 207 SRX-246 - Drug Profile 208 Stem Cell Therapy for Huntington's Disease - Drug Profile 210 Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 211 Stem Cell Therapy to Activate BDNF for Huntington's Disease - Drug Profile 214 Stem Cell Therapy to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 215 Synthetic Peptide to Inhibit Calmodulin for Huntington's Disease - Drug Profile 217 Synthetic Peptides for Central Nervous System Disorders - Drug Profile 218 Synthetic Peptides for Huntington's Disease - Drug Profile 219 UX-007 - Drug Profile 221 Vaccine for Huntington's Disease - Drug Profile 223 VCE-003 - Drug Profile 224 VCE-0032 - Drug Profile 225 VX-15 - Drug Profile 226 VYHTT-01 - Drug Profile 228 WT-501 - Drug Profile 229 XJB-5131 - Drug Profile 230 Huntington's Disease - Recent Pipeline Updates 231 Huntington's Disease - Dormant Projects 289 Huntington's Disease - Discontinued Products 295 Huntington's Disease - Product Development Milestones 296 Featured News & Press Releases 296 Appendix 302 Methodology 302 Coverage 302 Secondary Research 302 Primary Research 302 Expert Panel Validation 302 Contact Us 302 Disclaimer 303
List of Tables
Number of Products under Development for Huntington's Disease, H2 2015 19 Number of Products under Development for Huntington's Disease - Comparative Analysis, H2 2015 20 Number of Products under Development by Companies, H2 2015 22 Number of Products under Development by Companies, H2 2015 (Contd..1) 23 Number of Products under Development by Companies, H2 2015 (Contd..2) 24 Number of Products under Development by Companies, H2 2015 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2015 27 Comparative Analysis by Late Stage Development, H2 2015 28 Comparative Analysis by Clinical Stage Development, H2 2015 29 Comparative Analysis by Early Stage Development, H2 2015 30 Products under Development by Companies, H2 2015 31 Products under Development by Companies, H2 2015 (Contd..1) 32 Products under Development by Companies, H2 2015 (Contd..2) 33 Products under Development by Companies, H2 2015 (Contd..3) 34 Products under Development by Companies, H2 2015 (Contd..4) 35 Products under Investigation by Universities/Institutes, H2 2015 36 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 37 Huntington's Disease - Pipeline by Addex Therapeutics Ltd, H2 2015 38 Huntington's Disease - Pipeline by AFFiRiS AG, H2 2015 39 Huntington's Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 40 Huntington's Disease - Pipeline by Angita B.V., H2 2015 41 Huntington's Disease - Pipeline by Astellas Pharma Inc., H2 2015 42 Huntington's Disease - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 43 Huntington's Disease - Pipeline by BioCrea GmbH, H2 2015 44 Huntington's Disease - Pipeline by BioMarin Pharmaceutical Inc., H2 2015 45 Huntington's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015 46 Huntington's Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 47 Huntington's Disease - Pipeline by Chronos Therapeutics Limited, H2 2015 48 Huntington's Disease - Pipeline by EncephRx, Inc., H2 2015 49 Huntington's Disease - Pipeline by Evotec AG, H2 2015 50 Huntington's Disease - Pipeline by Galenea Corp., H2 2015 51 Huntington's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015 52 Huntington's Disease - Pipeline by Genethon, H2 2015 53 Huntington's Disease - Pipeline by Ipsen S.A., H2 2015 54 Huntington's Disease - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 55 Huntington's Disease - Pipeline by Kadmon Corporation, LLC, H2 2015 56 Huntington's Disease - Pipeline by KineMed, Inc., H2 2015 57 Huntington's Disease - Pipeline by Living Cell Technologies Limited, H2 2015 58 Huntington's Disease - Pipeline by Medesis Pharma S.A., H2 2015 59 Huntington's Disease - Pipeline by Neuralstem, Inc., H2 2015 60 Huntington's Disease - Pipeline by Neurimmune Holding AG, H2 2015 61 Huntington's Disease - Pipeline by NeuroNascent, Inc., H2 2015 62 Huntington's Disease - Pipeline by New World Laboratories, Inc., H2 2015 63 Huntington's Disease - Pipeline by nLife Therapeutics, S.L., H2 2015 64 Huntington's Disease - Pipeline by NsGene A/S, H2 2015 65 Huntington's Disease - Pipeline by Omeros Corporation, H2 2015 66 Huntington's Disease - Pipeline by Oryzon Genomics S.A., H2 2015 67 Huntington's Disease - Pipeline by Pfizer Inc., H2 2015 68 Huntington's Disease - Pipeline by PharmatrophiX, Inc., H2 2015 69 Huntington's Disease - Pipeline by Prana Biotechnology Limited, H2 2015 70 Huntington's Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2015 71 Huntington's Disease - Pipeline by QR Pharma, Inc., H2 2015 72 Huntington's Disease - Pipeline by Raptor Pharmaceuticals Inc, H2 2015 73 Huntington's Disease - Pipeline by reMYND NV, H2 2015 74 Huntington's Disease - Pipeline by RestorGenex Corporation, H2 2015 75 Huntington's Disease - Pipeline by Rhenovia Pharma Limited, H2 2015 76 Huntington's Disease - Pipeline by Sangamo BioSciences, Inc., H2 2015 77 Huntington's Disease - Pipeline by SOM Innovation Biotech SL, H2 2015 78 Huntington's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 79 Huntington's Disease - Pipeline by TyrNovo Ltd., H2 2015 80 Huntington's Disease - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015 81 Huntington's Disease - Pipeline by uniQure N.V., H2 2015 82 Huntington's Disease - Pipeline by Vaccinex, Inc., H2 2015 83 Huntington's Disease - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 84 Huntington's Disease - Pipeline by VistaGen Therapeutics , Inc., H2 2015 85 Huntington's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015 86 Huntington's Disease - Pipeline by Voyager Therapeutics, Inc., H2 2015 87 Huntington's Disease - Pipeline by Vybion, Inc., H2 2015 88 Huntington's Disease - Pipeline by Zenobia Therapeutics, Inc., H2 2015 89 Assessment by Monotherapy Products, H2 2015 90 Number of Products by Stage and Target, H2 2015 92 Number of Products by Stage and Mechanism of Action, H2 2015 95 Number of Products by Stage and Route of Administration, H2 2015 98 Number of Products by Stage and Molecule Type, H2 2015 100 Huntington's Disease Therapeutics - Recent Pipeline Updates, H2 2015 239 Huntington's Disease - Dormant Projects, H2 2015 297 Huntington's Disease - Dormant Projects (Contd..1), H2 2015 298 Huntington's Disease - Dormant Projects (Contd..2), H2 2015 299 Huntington's Disease - Dormant Projects (Contd..3), H2 2015 300 Huntington's Disease - Dormant Projects (Contd..4), H2 2015 301 Huntington's Disease - Dormant Projects (Contd..5), H2 2015 302 Huntington's Disease - Discontinued Products, H2 2015 303
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
